By

weareoku

New Life Sciences Examples to Help Examiners (and Applicants) Interpret and Apply the Subject Matter Eligibility Analysis under 35 USC § 101 in View of SCOTUS and CAFC Case Law: Nothing Much New

 On May 6, 2016, the USPTO issued several documents (http://www.uspto.gov/patent/laws-and-regulations/examination-policy/2014-interim-guidance-subject-matter-eligibility-0), including new Subject Matter Eligibility Examples for Life Sciences (including one that is directed to...

Are Proactive Portfolio Reviews Needed After 2015 Gilead Double Patenting Decision?

Gilead Sciences, Inc., Hoffmann-La Roche, Inc., F. Hoffmann-La Roche, Ltd., and Genentech, Inc., v.Natco Pharma Ltd.and Natco Pharma, Inc., 753 F.2d 1208 (Fed. Cir. 2014,...

Means plus Function Claims: The Federal Circuit’s Decision in Williamson v. Citrix Online LLC is Like Déjà vu All Over Again

It had all the elements of a pot-boiler thriller: a rogue government official orchestrating a mutiny against the rule of law, individuals in a plucky...

Update: From USPTO Patent Eligibility Guidelines

This is an update from our newsletter of January 2015. On July 30, 2015, the USPTO issued an update regarding the 2014 Interim Guidance on...

USPTO Introduces Expedited Patent Appeal Pilot

The USPTO is providing a temporary basis under which an appellant may have an ex parte appeal to the Patent Trial and Appeal Board (Board)...

International Design Patent Practice and Highlights of the New Hague Agreement

On May 13, 2015 the US will join the Hague Agreement opening a new path for international design patent fillings.  The overall concept of the...

Final Patent Term Adjustment Rules Issued

The USPTO issued final rules on January 9, 2015 implementing changes to the way in which Patent Term Adjustment (PTA) is calculated in viewof the recent Federal...

Updated Mayo/Myriad/Alice Patent Eligibility Interim Guidance

On December 16, 2014, the USPTO finally issued updated and significantly revised Interim Guidance to the Examiners for examination of patent claims for patent eligibility,...

Federal Circuit’s denial of rehearing Bristol-Myers Squibb v. Teva regarding Entecavir exposes potential issues regarding the utility of later found unexpected results for overcoming obviousness

In the earlier panel opinion, Entecavir was found obvious under the lead compound analysis over a structurally close compound 2’-CDG, which compound at the time...
1 2 3 4 5 6 8

Categories

MWZB Newsletter Signup

Subscribe